Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients
Not yet recruiting
- Conditions
- Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients
- Registration Number
- NCT05679648
- Lead Sponsor
- Sohag University
- Brief Summary
studying the prevalence of hepatic steatosis and fibrosis in a large scale of patients with RA and healthy controls
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- RA according to the American College of Rheumatology (ACR)/EULAR 2010 criteria (Aletaha et al., 2010)
- Age≥18 years
Exclusion Criteria
- History of hepatitis B and C virus infection.
- Receiving hepatotoxic drugs other than RA-specific drugs.
- Alcohol abuse (i30 g/day in men and ⩾20 g/day in women).
- Diagnosis of Wilson's disease, α1-antitrypsin deficiency or hemochromatosis.
- Autoimmune liver disease.
- Cancer.
- Pregnancy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method degree of hepatic fibrosis 1 day during examination degree of hepatic fibrosis by FIB-4 and APRI tests
degree of hepatic steatosis 1 day during examination degree of hepatic steatosis by ultrasonography and Hepatic Steatosis Index.
- Secondary Outcome Measures
Name Time Method